What guidance did Assertio Holdings's management provide for the next earnings period?

What is the revenue and EPS growth rate for Assertio Holdings year over year?

Did Assertio Holdings beat or miss consensus estimates last quarter?

What is the market's earnings forecast for Assertio Holdings next quarter?

What factors drove the changes in Assertio Holdings's revenue and profit?

What were the key takeaways from Assertio Holdings's earnings call?

What does Assertio Holdings do and what are its main business segments?

What is Assertio Holdings's gross profit margin?

- **Rolvedon Dominance**: Q3 sales of $38.6 million (up 157% YoY) drove narrowed full-year guidance, with a 2-quarter pull-forward enabling uninterrupted patient supply despite a temporary cash flow decline.
- **Sympazan Expansion**: 7.7% YoY growth to $2.8 million, supported by new clinical data highlighting oral film benefits for swallowing-challenged patients.
- **Indocin Resilience**: 15.8% YoY decline offset by Q3 price favorability, underscoring competitive pricing strategies in generics.
- **Financial Stability**: $93.4 million cash balance and stable 72% gross margin position the company for Rolvedon relaunch in Q2 2026.

**【CEO Summary Section】**
- Mark Reisenauer, the new CEO, highlighted the company's progress with Rolvedon and Sympazan, emphasizing their potential as core growth assets. Rolvedon net product sales reached $38.6 million in Q3 2025, up from $15 million in Q3 2024, driven by a 2-quarter pull-forward to ensure seamless supply during the transition to a consolidated commercial labeler. Sympazan sales grew to $2.8 million, up from $2.6 million in the prior year quarter, supported by new clinical data presented at the American Neurological Association Meeting.
- The company narrowed its full-year 2025 guidance to product sales of $110-112 million and adjusted EBITDA of $14-16 million, reflecting the pull-forward impact and ongoing generic competition in Indocin.

**【CFO Financial Commentary】**
- Total product sales for Q3 2025 were $49.5 million, up from $28.7 million in Q3 2024, with Rolvedon accounting for $38.6 million. Sympazan sales increased 7.7% year-over-year, while Indocin sales declined 15.8% due to generic competition.
- Gross margin decreased modestly to 72% (from 74% in Q3 2024) due to the higher proportion of Rolvedon sales. Adjusted EBITDA rose to $20.9 million, up from $4.4 million in Q3 2024. The company ended Q3 with $93.4 million in cash, expecting a temporary cash decline in Q4 2025 and Q1 2026 before resuming sales of the newly labeled Rolvedon in Q2 2026.

**【Q&A Key Highlights】**
- **Rolvedon Strategy**: Management reaffirmed price stability and predictability, with no direct link between labor code changes and ASP. The same-day dosing data will be published in a major journal, supporting clinical differentiation.
- **Indocin Performance**: Despite generic competition, Q3 sales showed slight volume growth and price favorability, reflecting competitive pricing strategies.
- **Sympazan Growth**: The oral film delivery mechanism remains a key differentiator, with targeted digital and field promotions in high-prescribing areas.
- **Gross Margin Outlook**: A.J. Patel indicated stable gross margins in line with Q3 levels, with no immediate changes to the 72% range.

Assertio Holdings, Inc. (ASRT) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

ASRT

ASRT fundamentals

You can ask Aime